Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial

NEXT STORY
Seventy-one scholars from 13 countries attended the 27th International Science Conference
PREV STORY
Gluconite Reviews – Alarming Customer Complaints or Fake Hidden Dangers?
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SELLAS Life Sciences Announces $10,700,000 Private Placement

- Financing Will Support Advancement of its Late-Stage Immuno-Oncology Pipeline - - Lead Candidate, ...

author_avatar
NASDAQ Market News

Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results

PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...

author_avatar
NASDAQ Market News

Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting

SAN CARLOS, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical ...

author_avatar
NASDAQ Market News